Company: HCTI
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112544
Chunk: 25

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 25
---
 applicable fees, commissions or discounts and over-allotment options will be set forth
in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will
also be set forth in a prospectus supplement.

Pursuant to General Instruction I.B.6 of Form
S-3, in no event will we sell our securities in public primary offerings with a value exceeding more than one-third of our public float
in any 12-month period so long as our public float remains below $75.0 million. As of January 4, 2024, the aggregate market value of our
outstanding common stock held by non- affiliates, or public float, was $7,241,244 based on 1,703,822 shares of our outstanding common
stock that were held by non-affiliates on such date and a price of $4.25 per share, which was the price at which our common stock was
last sold on the Nasdaq Capital Market on November 15, 2023, calculated in accordance with General Instruction I.B.6 of Form S-3. We have
not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the twelve-month period that ends on and includes
the date hereof. Our common stock is listed on The Nasdaq Capital Market under the symbol “HCTI.”

On January 2, 2024, the last reported sale price
of our common stock was $2.855 per share. The applicable prospectus supplement will contain information, where applicable, as to any other
listing, if any, on The Nasdaq Capital Market or any securities market or other securities exchange of the securities covered by the prospectus
supplement. Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities,
where applicable.

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should read carefully and consider the “Risk Factors” referenced on page 10 of this prospectus, as well as those contained in the applicable prospectus supplement and in the documents that are incorporated by reference herein or the applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Currently, we are an “emerging growth company” as